BACKGROUND: Glioblastoma is one of the most malignant brain tumors in adults and has a dismal prognosis. In a previous report, we reported that CD40, a TNF-R-related cell surface receptor, and its ligand CD40L were associated with glioma outcomes. Here we attempted to activate CD40 signaling in the tumor and determine if it exerted therapeutic efficacy. METHODS: CD40 expression was examined in 3 mouse glioma cell lines (GL261, NSCL61, and bRiTs-G3) and 5 human glioma cell lines (U87, U251, U373, T98, and A172). NSCL61 and bRiTs-G3, as glioma stem cells, also expressed the glioma stem cell markers MELK and CD44. In vitro, we demonstrated direct antitumor effects of an anti-CD40 agonistic monoclonal antibody (FGK45) against the cell lines. The efficacy of FGK45 was examined by local convection-enhanced delivery of the monoclonal antibody against each glioma model. RESULTS: CD40 was expressed in all mouse and human cell lines tested and was found at the cell membrane of each of the 3 mouse cell lines. FGK45 administration induced significant, direct antitumor effects in vitro. The local delivery of FGK45 significantly prolonged survival compared with controls in the NSCL61 and bRiTs-G3 models, but the effect was not significant in the GL261 model. Increases in apoptosis and CD4(+) and CD8(+) T cell infiltration were observed in the bRiTs-G3 model after FGK45 treatment. CONCLUSIONS: Local delivery of FGK45 significantly prolonged survival in glioma stem cell models. Thus, local delivery of this monoclonal antibody is promising for immunotherapy against gliomas.
BACKGROUND:Glioblastoma is one of the most malignant brain tumors in adults and has a dismal prognosis. In a previous report, we reported that CD40, a TNF-R-related cell surface receptor, and its ligand CD40L were associated with glioma outcomes. Here we attempted to activate CD40 signaling in the tumor and determine if it exerted therapeutic efficacy. METHODS:CD40 expression was examined in 3 mouseglioma cell lines (GL261, NSCL61, and bRiTs-G3) and 5 humanglioma cell lines (U87, U251, U373, T98, and A172). NSCL61 and bRiTs-G3, as glioma stem cells, also expressed the glioma stem cell markers MELK and CD44. In vitro, we demonstrated direct antitumor effects of an anti-CD40 agonistic monoclonal antibody (FGK45) against the cell lines. The efficacy of FGK45 was examined by local convection-enhanced delivery of the monoclonal antibody against each glioma model. RESULTS:CD40 was expressed in all mouse and human cell lines tested and was found at the cell membrane of each of the 3 mouse cell lines. FGK45 administration induced significant, direct antitumor effects in vitro. The local delivery of FGK45 significantly prolonged survival compared with controls in the NSCL61 and bRiTs-G3 models, but the effect was not significant in the GL261 model. Increases in apoptosis and CD4(+) and CD8(+) T cell infiltration were observed in the bRiTs-G3 model after FGK45 treatment. CONCLUSIONS: Local delivery of FGK45 significantly prolonged survival in glioma stem cell models. Thus, local delivery of this monoclonal antibody is promising for immunotherapy against gliomas.
Authors: R H Bobo; D W Laske; A Akbasak; P F Morrison; R L Dedrick; E H Oldfield Journal: Proc Natl Acad Sci U S A Date: 1994-03-15 Impact factor: 11.205
Authors: Robert H Vonderheide; Keith T Flaherty; Magi Khalil; Molly S Stumacher; David L Bajor; Natalie A Hutnick; Patricia Sullivan; J Joseph Mahany; Maryann Gallagher; Amy Kramer; Stephanie J Green; Peter J O'Dwyer; Kelli L Running; Richard D Huhn; Scott J Antonia Journal: J Clin Oncol Date: 2007-03-01 Impact factor: 44.544
Authors: Sumia Ali; Gwendalyn D King; James F Curtin; Marianela Candolfi; Weidong Xiong; Chunyan Liu; Mariana Puntel; Queng Cheng; Jesus Prieto; Antoni Ribas; Jerzy Kupiec-Weglinski; Nico van Rooijen; Hans Lassmann; Pedro R Lowenstein; Maria G Castro Journal: Cancer Res Date: 2005-08-15 Impact factor: 12.701
Authors: Connie Jackaman; Andrew M Lew; Yifan Zhan; Jane E Allan; Biljana Koloska; Peter T Graham; Bruce W S Robinson; Delia J Nelson Journal: Int Immunol Date: 2008-09-29 Impact factor: 4.823
Authors: Tyler J Van De Voort; Mildred A R Felder; Richard K Yang; Paul M Sondel; Alexander L Rakhmilevich Journal: J Immunother Date: 2013-01 Impact factor: 4.456
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: I Airoldi; S Lualdi; S Bruno; L Raffaghello; M Occhino; C Gambini; V Pistoia; M V Corrias Journal: Br J Cancer Date: 2003-05-19 Impact factor: 7.640
Authors: Wojciech K Panek; Katarzyna C Pituch; Jason Miska; Julius W Kim; Aida Rashidi; Deepak Kanojia; Aurora Lopez-Rosas; Yu Han; Dou Yu; Catalina Lee Chang; J Robert Kane; Peng Zhang; Alex Cordero; Maciej S Lesniak Journal: Mol Neurobiol Date: 2018-11-20 Impact factor: 5.590
Authors: Stephen J Bagley; Wei-Ting Hwang; Steven Brem; Gerald P Linette; Donald M O'Rourke; Arati S Desai Journal: J Neurooncol Date: 2018-10-23 Impact factor: 4.130
Authors: Fan Yang; Zhenqiang He; Hao Duan; Duo Zhang; Juehui Li; Huijuan Yang; Jay F Dorsey; Wei Zou; S Ali Nabavizadeh; Stephen J Bagley; Kalil Abdullah; Steven Brem; Lin Zhang; Xiaowei Xu; Katelyn T Byrne; Robert H Vonderheide; Yanqing Gong; Yi Fan Journal: Nat Commun Date: 2021-06-08 Impact factor: 14.919
Authors: Luuk van Hooren; Alessandra Vaccaro; Mohanraj Ramachandran; Konstantinos Vazaios; Sylwia Libard; Tiarne van de Walle; Maria Georganaki; Hua Huang; Ilkka Pietilä; Joey Lau; Maria H Ulvmar; Mikael C I Karlsson; Maria Zetterling; Sara M Mangsbo; Asgeir S Jakola; Thomas Olsson Bontell; Anja Smits; Magnus Essand; Anna Dimberg Journal: Nat Commun Date: 2021-07-05 Impact factor: 14.919